Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (181-190 of 627) with videos related to

Pageof 63
Sort By:
JACC. Heart Failure|April 4, 2024
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical SensorsFrancois Haddad, Antti Saraste, Kristiina M Santalahti, et al.
Journal of the American Heart Association|January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-AnalysisClare Arnott, Qiang Li, Amy Kang, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Emergency Medicine Journal : EMJ|July 29, 2008
Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctionsC D Miller, G J Fermann, C J Lindsell, et al.
Circulation. Cardiovascular Imaging|May 14, 2026
Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health StudyNancy Herrera-Leaño, Bettia Celestin, Everton Santana, et al.
Diabetes Care|December 4, 2014
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesBruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Diabetes, Obesity & Metabolism|February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trialJennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
Circulation|August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trialChristopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
American Heart Journal|March 7, 2021
Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trialMintu Turakhia, Vandana Sundaram, Shea N Smith, et al.
Journal of Affective Disorders|August 28, 2022
General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequityJulio C Nunes, Megan K Carroll, Kenneth W Mahaffey, et al.
Pageof 63

Showing results (181-190 of 627) with videos related to

Sort By:
Pageof 63
JACC. Heart Failure|April 4, 2024
Smartphone-Based Recognition of Heart Failure by Means of Microelectromechanical SensorsFrancois Haddad, Antti Saraste, Kristiina M Santalahti, et al.
Journal of the American Heart Association|January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-AnalysisClare Arnott, Qiang Li, Amy Kang, et al.
American Heart Journal|March 30, 2013
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryBenjamin A Steinberg, DaJuanicia N Holmes, Michael D Ezekowitz, et al.
Emergency Medicine Journal : EMJ|July 29, 2008
Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctionsC D Miller, G J Fermann, C J Lindsell, et al.
Circulation. Cardiovascular Imaging|May 14, 2026
Impact of the 2025 ASE Guidelines on the Classification of LV Diastolic Dysfunction in the Community: A Project Baseline Health StudyNancy Herrera-Leaño, Bettia Celestin, Everton Santana, et al.
Diabetes Care|December 4, 2014
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesBruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Diabetes, Obesity & Metabolism|February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trialJennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
Circulation|August 20, 2003
Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trialChristopher B Granger, Kenneth W Mahaffey, W Douglas Weaver, et al.
American Heart Journal|March 7, 2021
Efficacy of a centralized, blended electronic, and human intervention to improve direct oral anticoagulant adherence: Smartphones to improve rivaroxaban ADHEREnce in atrial fibrillation (SmartADHERE) a randomized clinical trialMintu Turakhia, Vandana Sundaram, Shea N Smith, et al.
Journal of Affective Disorders|August 28, 2022
General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequityJulio C Nunes, Megan K Carroll, Kenneth W Mahaffey, et al.
Pageof 63